Date: 2014-05-21
Type of information: Loan
Company: Lanthio Pharma (The Netherlands)
Investors: Dutch Government agency RVO (The Netherlands)
Amount: up to €3.6 million
Funding type: loan
Planned used: This Innovation Credit loan will support the development of LP2, an innovative lanthipeptide for treatment of Idiopathic Pulmonary Fibrosis. LP2 is the first peptide-based drug to selectively activate the Angiotensin type 2 (AT2) receptor of the Renin Angiotensin System (RAS). The natural role of the AT2 receptor is to protect damaged tissue against inflammation and fibrosis. Once safety and efficacy of LP2 is established in Idiopathic Pulmonary Fibrosis patients, application of LP2 could be extended to many other forms of fibrosis, including renal fibrosis, heart fibrosis and liver fibrosis. The loan covers up to 35% of development costs through to completion of Phase II human Proof of Concept trials.
Others: * On May 21, 2014, Lanthio Pharma, a biopharmaceutical company focused on discovering and developing lanthipeptides, announced that it has been awarded an Innovation Credit loan of up to €3.6 million by Dutch Government agency RVO. The Innovation Credit loan will support the development of LP2, an innovative lanthipeptide for treatment of Idiopathic Pulmonary Fibrosis.
Therapeutic area: Lung diseases
